New pill shows promise against rare lung cancer mutation
NCT ID NCT05466149
First seen Nov 19, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This study tests a daily pill called furmonertinib in about 100 people with advanced lung cancer that has a specific genetic change (EGFR exon 20 insertion) and has worsened after chemotherapy. The goal is to see if the drug can shrink tumors and control the disease. Participants take the medicine until it stops working or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Jilin Province Cancer Hospital
Changchun, Jilin, 130000, China
Conditions
Explore the condition pages connected to this study.